Citations

Clear

7552 citation(s) found for "Ku, Matthew".

0625 Prevalence of Subjective Longer Sleep Times and Sleepiness in Patients Evaluated at a Tertiary Medical Center
Chen, Xindi, Ruoff, Chad , Ruoff, Chad M , Buras, Matthew , Carvalho, Diego Z.

Mayo Clinic

SLEEP | April 20, 2024 | Volume: 47 | Issue: Supplement_1 | Pages: A267-A267

10.1093/sleep/zsae067.0625 Get It

Abstract Introduction The ICSD-3-TR defines idiopathic hypersomnia in terms of objective sleep times as sleeping at least 11 hours using 24-hour polysomnography or wrist actigraphy averaged over at least 7 days. Published studies on sleep duration are generally limited by lower sleep duration cut-offs (e.g., ≥ 9 hours), so prevalence data on longer sleep durations are missing. This study used clinical questionnaire data from Mayo Clinic patients to characterize longer sleep times and excessive daytime sleepiness in this population. Methods We retrospectively identified patients who answered questions about subjective sleep times and excessive daytime sleepiness, using the Epworth Sleepiness Scale (ESS), as part of their evaluation in a sleep clinic across the Mayo Clinic Enterprise from 2017 to 2023. Demographic data and sleep disorder diagnoses were then analyzed. Results Patients (N=25,480) with subjective nocturnal sleep times of ≥ 9 (n=2721, 10.7%), ≥ 10 (n=1059, 4.2%), and ≥ 11 hours (n=349, 1.4%) had an ESS ≥ 10 in 33.5%, 41.0%, and 51.3% of the time, respectively. 3.6% (age 53.2±19.7; 58.9% female), 1.7% (age 53.1±20.4; 58.1% female), and 0.7% (age 49.8±19.9; 58.1% female) of the patients reported an ESS ≥ 10 and subjective nocturnal sleep times of ≥ 9, ≥ 10, and ≥ 11 hours per night, respectively. After adjusting for age and sex, patients with more than one diagnostic entry compared to those with one or fewer diagnostic entries for idiopathic hypersomnia with long sleep time (OR=12.75, 95% CI [6.09, 24.52], p< 0.001) and narcolepsy with cataplexy (OR=5.53, 95% CI [1.31, 15.84], p=0.005) were significantly more likely to report ESS ≥ 10 and subjective nocturnal sleep times ≥ 11 hours per night. Conclusion Less than 1% of patients presenting to a Mayo Clinic sleep specialist have self-reported metrics (i.e., ESS ≥ 10 and subjective nocturnal sleep times ≥ 11 per night) consistent with basic clinical features of idiopathic hypersomnia with long sleep time. Additional data analyses (e.g., comorbid conditions, social history, and laboratory results) are underway. Support (if any)
Stripping versus ligation of vas deferens in microscopic denervation of spermatic cord in men with chronic orchialgia: A multicenter study
El‐Achkar, Adnan , Hammad, Muhammed , Barham, David , Service, C Austin, Hsieh, Tung- Chin, Mills, Jesse N. , Ziegelmann, Matthew , Smith, Ryan P. , Bernie, Helen L. , Egert, Melissa , Gross, Kelli, Pastuszak, Alex, Hotaling, James M. , Yafi, Faysal A. , Hammad, Muhammed A M , Patel, Darshan P. , Kianian, Reza , Eleswarapu, Sriram Venkata , Bryk, Darren J. , Raheem, Omer A. , Fendereski, Kiarad

Mayo Clinic

Andrology | April 19, 2024 | Volume: 13 | Issue: 2 | Pages: 268-274

10.1111/andr.13650 | PMID 38639020 Get It

AbstractBackgroundMicrodenervation of the spermatic cord (MSCD) is an effective treatment modality for men with intractable scrotal content pain. For patients not interested in preserving fertility, some centers advocate ligation of the vas during denervation, while others prefer stripping of the vas deferens to preserve the vasal artery, hence preserving vasculature to the testis and possibly decreasing post‐operative congestion pain.ObjectiveTo compare outcomes of patients with chronic orchialgia, who underwent MSCD by either stripping or ligating the vas deferens.Materials and methodsA retrospective chart review of 85 patients who underwent MSCD from 2017–2023 was performed. Patients’ demographics including history of prior surgical procedures were recorded. Response to surgery was evaluated as either complete resolution of pain, partial resolution of pain, or no improvement in pain.ResultsEighty‐five patients underwent MSCD with a median (interquartile range, IQR) age of 36 (25.5–46.5) years and median duration of pain of 16 (6–31) months. Thirty‐seven patients underwent stripping of vas, while 48 underwent ligation of vas during MSCD. Median follow up was 12 months. Twenty‐one (43.5%) patients had prior inguinal scrotal surgery in the ligation group compared to 5 (13.5%) in the stripping group, p = 0.003. The etiology of pain was similar between the groups. The response to MSCD between the two groups was similar, 67.6% of patients who underwent stripping had complete resolution of pain versus 66.7% of those who had ligation (p = 0.968), with similar rates of post‐operative complications (p‐value = 0.132).ConclusionsIn men with intractable chronic scrotal content pain with no interest in preserving fertility, ligation, or stripping of the vas deferens yields similar outcomes with regard to pain resolution. Both techniques are safe with no reports of any testicular atrophy.
Soft Pink Plaques at Site of Breast Cancer Vaccination: Challenge
Wang, Katherine , Hall, Matthew R., Chumsri, Saranya , Wang, Katherine L , Sokumbi, Olayemi

Mayo Clinic

The American Journal of Dermatopathology | April 18, 2024 | Volume: 46 | Issue: 5 | Pages: e29-e30

10.1097/dad.0000000000002682 | PMID 40008804 Get It

Soft Pink Plaques at the Site of Breast Cancer Vaccination: Answer
Wang, Katherine , Hall, Matthew R., Chumsri, Saranya , Wang, Katherine L , Sokumbi, Olayemi

Mayo Clinic

The American Journal of Dermatopathology | April 18, 2024 | Volume: 46 | Issue: 5 | Pages: 320-321

10.1097/dad.0000000000002683 | PMID 40008799 Get It

TOpCLASS Expert Consensus Classification of Perianal Fistulising Crohn’s Disease: A Real-world Application in a Serial Fistula MRI Cohort
Schroeder, Matthew , Abushamma, Suha , George, Alvin T , Ravella, Balakrishna , Hickman, John A. , Elumalai, Anusha, Ludwig, Daniel R. , Viswanath, Satish E. , Schroeder, Matthew K , Sebastian, Shaji , Ballard, David H , Deepak, Parakkal , Viswanath, Satish E , Hickman, John, Wise, Paul E. , Zulfiqar, Maria , Shetty, Anup S. , Luo, Chongliang , Ballard, David H. , Deepak, Parakkal

Mayo Clinic

Journal of Crohn's and Colitis | April 18, 2024 | Volume: 18 | Issue: 9 | Pages: 1430-1439

10.1093/ecco-jcc/jjae056 | PMID 38642332 Get It

Abstract Background and Aims Perianal fistuliing Crohn’s disease [PFCD] is an aggressive phenotype of Crohn’s disease defined by frequent relapses and disabling symptoms. A novel consensus classification system was recently outlined by the TOpCLASS consortium, which seeks to unify disease severity with patient-centred goals but has not yet been validated. We aimed to apply this to a real-world cohort and to identify factors that predict transition between classes over time. Methods We identified all patients with PFCD and at least one baseline and one follow-up pelvic MRI [pMRI]. TOpCLASS classification, disease characteristics, and imaging indices were collected retrospectively at time periods corresponding with respective MRIs. Results We identified 100 patients with PFCD, of whom 96 were assigned TOpCLASS Classes 1–2c at baseline. Most patients [78.1%] started in Class 2b, but changes in classification were observed in 52.1% of all patients. Male sex [72.0%, 46.6%, 40.0%, p = 0.03] and prior perianal surgery [52.0% vs 44.6% vs 40.0%, p = 0.02] were more frequently observed in those with improved class compared to unchanged and worsened class. Baseline pMRI indices were not associated with changes in classification; however, greater improvements in mVAI, MODIFI-CD, and PEMPAC were seen among those who improved. Linear mixed effect modelling identified only male sex [-0.31, 95% CI -0.60 to -0.02] with improvement in class. Conclusion The TOpCLASS classification highlights the dynamic nature of PFCD over time. However, our ability to predict transitions between classes remains limited and requires prospective assessment. Improvement in MRI index scores over time was associated with a transition to lower TOpCLASS classification.
Role of Routine Suppressive Antibiotic Therapy After Debridement, Antibiotics, and Implant Retention for Acute Periprosthetic Joint Infections
Tai, Don Bambino Geno , Tande, Aaron J. , Langworthy, Benjamin , Abdel, Matthew P. , Berbari, Elie F. , Jutte, Paul C. , Soriano, Àlex , Suh, Gina A. , Wouthuyzen‐Bakker, Marjan , Jutte, Paul , Soriano, Alex , Suh, Gina A , Wouthuyzen-Bakker, Marjan , Tande, Aaron , Abdel, Matthew P , Tai, Don Bambino Geno , Have, Bas ten, Zijlstra, Wierd Pieter

Mayo Clinic

Open Forum Infectious Diseases | April 17, 2024 | Volume: 11 | Issue: 5 | Pages: No page available

10.1093/ofid/ofae216 | PMID 38778861 Get It

Abstract Background The first-line management strategy for acute periprosthetic joint infections (PJIs) is debridement, antibiotics, and implant retention (DAIR). Suppressive antibiotic therapy (SAT) after DAIR is proposed to improve outcomes, yet its efficacy remains under scrutiny. Methods We conducted a multicenter retrospective study in patients with acute PJI of the hip or knee who were treated with DAIR in centers from Europe and the United States. We analyzed the effect of SAT using a Cox model landmarked at 12 weeks. The primary covariate of interest was SAT, which was analyzed as a time-varying covariate. Patients who experienced treatment failure or were lost to follow-up within 12 weeks were excluded from the analysis. Results The study included 510 patients with 66 treatment failures with a median follow-up of 801 days. We did not find a statistically significant association between SAT and treatment failure (hazard ratio, 1.37; 95% CI, .79–2.39; P = .27). Subgroup analyses for joint, country cohort, and type of infection (early or late acute) did not show benefit for SAT. Secondary analysis of country cohorts showed a trend toward benefit for the US cohort (hazard ratio, 0.36; 95% CI, .11–1.15; P = .09), which also had the highest risk of treatment failure. Conclusions The utility of routine SAT as a strategy for enhancing DAIR's success in acute PJI remains uncertain. Our results suggest that SAT's benefits might be restricted to specific groups of patients, underscoring the need for randomized controlled trials. Identifying patients most likely to benefit from SAT should be a priority in future studies.
Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction
Silvestry, Frank E. , Komtebedde, Jan , Solomon, Scott D. , Price, Matthew J. , Kawash, Rami, Hummel, Scott L. , Cutlip, Donald E. , Leon, Martin B. , Veldhuisen, Dirk J. van , Rieth, Andreas , Bugger, Heiko , Mazurek, Jeremy A. , Ky, Bonnie , Ky, Bonnie , Hummel, Scott L , Patel, Ravi B. , Solomon, Scott David , Hasenfuß, Gerd , Litwin, Sheldon E. , Borlaug, Barry A. , McKenzie, Scott , Kapadia, Samir , Vanderheyden, Marc , Shah, Sanjiv J

Mayo Clinic

JAMA Cardiology | April 17, 2024 | Volume: 9 | Issue: 6 | Pages: 507

10.1001/jamacardio.2024.0520 | PMID 38630494 Get It

Importance Although the results of A Study to Evaluate the Corvia Medical Inc IASD System II to Reduce Elevated Left Atrial Pressure in Patients with Heart Failure (REDUCE LAP-HF II) trial were neutral overall, atrial shunt therapy demonstrated potential efficacy in responders (no latent pulmonary vascular disease and no cardiac rhythm management device). Post hoc analyses were conducted to evaluate the effect of shunt vs sham stratified by responder status. Objective To evaluate the effect of atrial shunt vs sham control on cardiac structure/function in the overall study and stratified by responder status. Design, Setting, and Participants This was a sham-controlled randomized clinical trial of an atrial shunt device in heart failure with preserved ejection fraction (HFpEF)/HF with mildly reduced EF (HFmrEF). Trial participants with evaluable echocardiography scans were recruited from 89 international medical centers. Data were analyzed from April 2023 to January 2024. Interventions Atrial shunt device or sham control. Main Outcome Measures Changes in echocardiographic measures from baseline to 1, 6, 12, and 24 months after index procedure. Results The modified intention-to-treat analysis of the REDUCE LAP-HF II trial included 621 randomized patients (median [IQR] age, 72.0 [66.0-77.0] years; 382 female [61.5%]; shunt arm, 309 [49.8%]; sham control arm, 312 [50.2%]). Through 24 months, 212 of 217 patients (98%) in the shunt arm with evaluable echocardiograms had patent shunts. In the overall trial population, the shunt reduced left ventricular (LV) end-diastolic volume (mean difference, −5.65 mL; P <.001), left atrial (LA) minimal volume (mean difference, −2.8 mL; P =.01), and improved LV systolic tissue Doppler velocity (mean difference, 0.69 cm/s; P <.001) and LA emptying fraction (mean difference, 1.88 percentage units; P =.02) compared with sham. Shunt treatment also increased right ventricular (RV; mean difference, 9.58 mL; P <.001) and right atrial (RA; mean difference, 9.71 mL; P <.001) volumes but had no effect on RV systolic function, pulmonary artery pressure, or RA pressure compared with sham. In the shunt arm, responders had smaller increases in RV end-diastolic volume (mean difference, 5.71 mL vs 15.18 mL; interaction P =.01), RV end-systolic volume (mean difference, 1.58 mL vs 7.89 mL; interaction P =.002), and RV/LV ratio (mean difference, 0.07 vs 0.20; interaction P <.001) and larger increases in transmitral A wave velocity (mean difference, 5.08 cm/s vs −1.97 cm/s; interaction P =.02) compared with nonresponders randomized to the shunt, suggesting greater ability to accommodate shunted blood through the pulmonary circulation enabling LA unloading. Conclusions and Relevance In this post hoc analysis of the REDUCE LAP-HF II trial, over 2 years of follow-up, atrial shunting led to reverse remodeling of left-sided chambers and increases in volume of right-sided chambers consistent with the shunt flow but no change in RV systolic function compared with sham. Changes in cardiac structure/function were more favorable in responders compared with nonresponders treated with the shunt, supporting the previously identified responder group hypothesis and mechanism, although further evaluation with longer follow-up is needed. Trial Registration ClinicalTrials.gov Identifier: NCT03088033
Color VISION for improved ultrasound visualization of brachytherapy needles
Dupere, Justine M , Brost, Eric E., Hainy, Matthew E, Lee, Christine U. , Stish, Bradley J. , Deufel, Christopher L. , Dupere, Justine , Brost, Eric, Urban, Matthew W.

Mayo Clinic

Medical Physics | April 17, 2024 | Volume: 51 | Issue: 6 | Pages: 4340-4350

10.1002/mp.17083 | PMID 38629912 Get It

AbstractBackgroundHigh dose rate brachytherapy is commonly used in the treatment of prostate cancer. Treatment planning is often performed under transrectal ultrasound (US) guidance, but brachytherapy needles can be challenging to digitize due to the presence of poor US conspicuity and imaging artifacts. The plan accuracy and quality, however, are dependent on the proper visualization of the needles with millimeter accuracy.PurposeThis work describes a technique for generating a color overlay of needle locations atop the grayscale US image. Prototype devices were developed to produce vibrations in the brachytherapy needles that generate a high contrast color Doppler (CD) signal that highlights the needle locations with superior contrast and reduced artifacts. Denoted by the acronym color VISION (Vibrationally Induced Shimmering for Identifying an Object's Nature), the technology has the potential to improve applicator conspicuity and facilitate automated applicator digitization.MethodsThree prototype vibrational devices with frequencies between 200–450 Hz were designed in‐house and evaluated with needle implants in a phantom and cadaveric male pelvis using: (1) an actuator attached to the front of a prostate needle template; (2) an actuator attached to the top of the needle template; and (3) a hand‐held actuator with a stylet, inserted directly into a needle's inner lumen. Acquired images were postprocessed in MATLAB to evaluate the potential for automated digitization.ResultsAll prototype devices produced localized shimmering in implanted brachytherapy needles in both the axial and sagittal planes. The template mounted actuators provided better vibrational coupling and ease of operation than the stylet prototype. The Michelson contrast, or visibility, of the shimmering CD signal was 100% compared with ≤40% for B‐mode imaging of a single needle. Proof‐of‐principle for automated applicator digitization using only the CD signal was demonstrated.ConclusionsThe color VISION prototype devices successfully coupled mechanical vibrations into brachytherapy needles to generate US CD shimmering and accurately highlight brachytherapy needle locations. The high contrast and natively registered signal are promising for future work to automate the needle digitization and provide a real‐time visual overlay of the applicator on the B‐mode US image.
Assessment of management reasoning: Design considerations drawn from analysis of simulated outpatient encounters
Cook, David A. , Durning, Steven J. , Stephenson, Christopher R. , Gruppen, Larry D. , Lineberry, Matt , Lineberry, Matthew

Mayo Clinic

Medical Teacher | April 17, 2024 | Volume: 47 | Issue: 2 | Pages: 218-232

10.1080/0142159x.2024.2337251 | PMID 38627020 Get It

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024
Wierda, William G. , Brown, Jennifer R. , Bilgrami, S, Bociek, Greg, Brander, Danielle M. , Cortese, Matthew J , Cripe, Larry D., Davis, Randall S. , Eradat, Herbert, Fakhri, Bita , Fletcher, Christopher D.�M. , Gaballa, Sameh , Hamid, Muhammad Saad , Hill, Brian T. , Kaesberg, Paul, Kamdar, Manali , Ma, Shuo , Mosse, Claudio A. , Nakhoda, Shazia , Schorr, Andrew, Seshadri, Madhav , Stephens, Deborah M. , Ujjani, Chaitra S. , Valdez, Riccardo, Wagner‐Johnston, Nina D. , Woyach, Jennifer A. , Sundar, Hema, Dwyer, Mary A., Stephens, Deborah M , Kamdar, Manali , Ma, Shuo , Fakhri, Bita , Wierda, William G. , Abramson, Jeremy S. , Awan, Farrukh T. , Kahl, Brad S. , Kipps, Thomas J. , Parikh, Sameer A. , Schuster, Stephen J. , Siddiqi, Tanya , Thompson, Meghan C

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 16, 2024 | Volume: 22 | Issue: 3 | Pages: 175-204

10.6004/jnccn.2024.0018 | PMID 38626800 Get It

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are essentially different manifestations of the same disease that are similarly managed. A number of molecular and cytogenetic variables with prognostic implications have been identified. Undetectable minimal residual disease at the end of treatment with chemoimmunotherapy or venetoclax-based combination regimens is an independent predictor of improved survival among patients with previously untreated or relapsed/refractory CLL/SLL. The selection of treatment is based on the disease stage, presence or absence of del(17p) or TP53 mutation, immunoglobulin heavy chain variable region mutation status, patient age, performance status, comorbid conditions, and the agent’s toxicity profile. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with CLL/SLL.